+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

North America Uveitis Treatment Market, by Drug Class, by Disease Type, by Distribution Channel, by Country, Industry Analysis and Forecast, 2019 - 2025

  • ID: 5017811
  • Report
  • March 2020
  • Region: North America
  • 78 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
The North America Uveitis Treatment Market is expected to witness market growth of 4.98% CAGR during the forecast period (2019-2025).

Iontophoresis is the use of electric current to help move molecules through the epithelium of the hydrophilic cornea, traditionally the greatest barrier to the penetration of medicines into the eye. It is expected to potentially increase the steroid medication's bioavailability, allowing for significantly reduced dosing frequency and improved effectiveness compared to topical corticosteroids. This procedure has the advantage of not being connected to many of the needle-related complications associated with many local procedures.

Treatment of post-infectious uveitis is a medical problem for ophthalmologists. The eye is a privileged site, preserved by blood ocular barriers that restrict the penetration of systemic antimicrobials into the corresponding segment. Furthermore, intraocularly, topical and subconjunctival treatments are unable to generate adequate concentrations of the medicines. Post-infectious uveitis can result from bacteria, viruses, fungi, or protozoa. The treatment method varies widely depending on the etiology of infections.

Based on Drug Class, the market is segmented into Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs and Other Drug Class. Based on Disease Type, the market is segmented into Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis and Panuveitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online stores. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Alimera Sciences, Inc., Enzo Biochem, Inc., Amgen, Inc., Bausch Health Companies, Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., TopiVert Ltd., and Novartis AG.

Scope of the Study

Market Segmentation:

By Drug Class
  • Anti-inflammatory
  • Immunotherapy & Targeted Therapies
  • Antimicrobial Drugs
  • Other Drug Class
By Disease Type
  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online stores
By Country
  • US
  • Canada
  • Mexico
  • Rest of North America
Companies Profiled
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Amgen, Inc.
  • Enzo Biochem, Inc.
  • Novartis AG
  • TopiVert Ltd.
  • MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Uveitis Treatment Market, by Drug Class
1.4.2 North America Uveitis Treatment Market, by Disease Type
1.4.3 North America Uveitis Treatment Market, by Distribution Channel
1.4.4 North America Uveitis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Uveitis Treatment Market by Drug Class
3.1 North America Anti-inflammatory Market by Country
3.2 North America Immunotherapy & Targeted Therapies Market by Country
3.3 North America Antimicrobial Drugs Market by Country
3.4 North America Other Drug Class Market by Country

Chapter 4. North America Uveitis Treatment Market by Disease Type
4.1 North America Anterior Uveitis Market by Country
4.2 North America Posterior Uveitis Market by Country
4.3 North America Intermediate Uveitis Market by Country
4.4 North America Other Disease Types Market by Country

Chapter 5. North America Uveitis Treatment Market by Distribution Channel
5.1 North America Hospital Pharmacies Market by Country
5.2 North America Retail Pharmacies Market by Country
5.3 North America Online stores Market by Country

Chapter 6. North America Uveitis Treatment Market by Country
6.1 USA Uveitis Treatment Market
6.1.1 USA Uveitis Treatment Market by Drug Class
6.1.2 USA Uveitis Treatment Market by Disease Type
6.1.3 USA Uveitis Treatment Market by Distribution Channel
6.2 Canada Uveitis Treatment Market
6.2.1 Canada Uveitis Treatment Market by Drug Class
6.2.2 Canada Uveitis Treatment Market by Disease Type
6.2.3 Canada Uveitis Treatment Market by Distribution Channel
6.3 Mexico Uveitis Treatment Market
6.3.1 Mexico Uveitis Treatment Market by Drug Class
6.3.2 Mexico Uveitis Treatment Market by Disease Type
6.3.3 Mexico Uveitis Treatment Market by Distribution Channel
6.4 Rest of North America Uveitis Treatment Market
6.4.1 Rest of North America Uveitis Treatment Market by Drug Class
6.4.2 Rest of North America Uveitis Treatment Market by Disease Type
6.4.3 Rest of North America Uveitis Treatment Market by Distribution Channel

Chapter 7. Company Profiles
7.1 AbbVie, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals:
7.2 Alimera Sciences, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expense
7.2.1 Recent strategies and developments:
7.2.1.1 Product Launches and Product Expansions:
7.3 Enzo Biochem, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Research & Development Expense
7.4.4 Recent strategies and developments:
7.4.4.1 Product Launches and Product Expansions:
7.4.4.2 Partnerships, Collaborations, and Agreements:
7.5 Bausch Health Companies, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Clearside Biomedical, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Research & Development Expense
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 EyePoint Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.7.5.2 Acquisition and Mergers:
7.8 Santen Pharmaceutical Co., Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Topivert Ltd.
7.9.1 Company Overview
7.1 Novartis AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Recent strategies and developments:
7.10.4.1 Acquisition and Mergers:
7.10.4.2 Approvals:
7.10.5 Research & Development Expense
Note: Product cover images may vary from those shown
3 of 4
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Enzo Biochem, Inc.
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • TopiVert Ltd.
  • Novartis AG
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll